These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18279775)

  • 21. Management of heart failure: a brief review and selected update.
    Unzek S; Francis GS
    Cardiol Clin; 2008 Nov; 26(4):561-71. PubMed ID: 18929231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing outcomes in the patient with acute decompensated heart failure.
    Mehra MR
    Am Heart J; 2006 Mar; 151(3):571-9. PubMed ID: 16504617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
    J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapies for heart failure.
    Riggs JM
    RN; 2004 Mar; 67(3):28-32; quiz 33. PubMed ID: 15065491
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
    Branzi G; Malfatto G; Villani A; Ciambellotti F; Revera M; Giglio A; Rosa FD; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):662-8. PubMed ID: 20613551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of levosimendan on right ventricular function in patients with advanced heart failure.
    Parissis JT; Paraskevaidis I; Bistola V; Farmakis D; Panou F; Kourea K; Nikolaou M; Filippatos G; Kremastinos D
    Am J Cardiol; 2006 Dec; 98(11):1489-92. PubMed ID: 17126656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic stabilization and management of acute heart failure syndromes in the emergency department.
    Kirk JD; Parissis JT; Filippatos G
    Heart Fail Clin; 2009 Jan; 5(1):43-54, vi. PubMed ID: 19026385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New and emerging drug therapies for the management of acute heart failure.
    Krum H; Liew D
    Intern Med J; 2003 Nov; 33(11):515-20. PubMed ID: 14656255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasodilators in the management of acute heart failure.
    Elkayam U; Janmohamed M; Habib M; Hatamizadeh P
    Crit Care Med; 2008 Jan; 36(1 Suppl):S95-105. PubMed ID: 18158484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 31. Seeking new heights in acute heart failure syndromes: lessons from ASCEND and EVEREST.
    Konstam MA; Pang PS; Gheorghiade M
    Eur Heart J; 2013 May; 34(18):1345-9. PubMed ID: 21821847
    [No Abstract]   [Full Text] [Related]  

  • 32. Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
    Moertl D; Berger R; Huelsmann M; Bojic A; Pacher R
    Eur J Heart Fail; 2005 Dec; 7(7):1156-63. PubMed ID: 16084762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [What is new in the medical management of acute heart failure?].
    Meyer P; White M; Keller RF; Lerch R; Hullin R
    Rev Med Suisse; 2010 Jun; 6(252):1211-7. PubMed ID: 20614757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes?
    Khan H; Metra M; Blair JE; Vogel M; Harinstein ME; Filippatos GS; Sabbah HN; Porchet H; Valentini G; Gheorghiade M
    Heart Fail Rev; 2009 Dec; 14(4):277-87. PubMed ID: 19238540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levosimendan: calcium sensitizer and inodilator.
    Milligan DJ; Fields AM
    Anesthesiol Clin; 2010 Dec; 28(4):753-60. PubMed ID: 21074750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of nesiritide in patients with acute decompensated heart failure.
    DeWald TA; Hernandez AF
    Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):159-69. PubMed ID: 20136602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.
    Cleland JG; Nikitin N; McGowan J
    Expert Rev Cardiovasc Ther; 2004 Jan; 2(1):9-19. PubMed ID: 15038409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. European experience on the practical use of levosimendan in patients with acute heart failure syndromes.
    Follath F; Franco F; Cardoso JS
    Am J Cardiol; 2005 Sep; 96(6A):80G-5G. PubMed ID: 16181827
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Review of current and investigational pharmacologic agents for acute heart failure syndromes.
    Shin DD; Brandimarte F; De Luca L; Sabbah HN; Fonarow GC; Filippatos G; Komajda M; Gheorghiade M
    Am J Cardiol; 2007 Jan; 99(2A):4A-23A. PubMed ID: 17239703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of acute decompensated heart failure: treatment, controversy, and future directions.
    Munger MA
    Pharmacotherapy; 2006 Aug; 26(8 Pt 2):131S-138S. PubMed ID: 16863479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.